Animal Models of Malignant Mesothelioma

REFERENCES

• Altomare D. A., Vaslet C. A., Skele K. L., DeRienzo A., Devarajan K., Jhanwar S. C., McClatchey A. I., Kane A. B., Testa J. R. A mouse model recapitulating molecular features of human mesothelioma. Cancer Res. 2005a; 65: 8090–8095, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Altomare D. A., You H., Xiao G.-H., Ramos-Niño M. E., Skele K. L., DeRienzo A., Jhanwar S. C., Mossman B. T., Kane A. B., Testa J. R. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 2005b; 24: 6080–6089, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Apostolou S., Balsara B. R., Testa J. R. Cytogenetics of malignant mesothelioma. Malignant mesothelioma: Advances in pathogenesis, diagnosis, and translational therapies, H. I. Pass, N. J. Vogelzang, M. Carbone. Springer Science & Business Media, New York 2005; 101–111
   Google Scholar
• Artandi S. E., Chang S., Lee S. L., Alson S., Gottlieb G. J., Chin L., DePinho R. A. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000; 406: 641–645, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Cacciotti P., Barbone D., Porta C., Altomare D. A., Testa J. R., Mutti L., Gaudino G. SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Res. 2005; 65: 5256–5262, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Craighead J. E., Kane A. B. The pathogenesis of malignant and nonmalignant serosal lesions in body cavities consequent to asbestos exposure. The mesothelial cell and mesothelioma, M.-C. Jaurand, J. Bignon. Marcel Dekker, New York 1994; 79–102
   Google Scholar
• Fleury-Feith J., Lecomte C., Renier A., Matrat M., Kheuang L., Abramowski V., Levy F., Janin A., Giovanni M., Jaurand M.-C. Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumors. Oncogene 2003; 22: 3799–3805, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Gazdar A. F., Butel J. S., Carbone M. SV40 and human tumours: Myth, association or causality?. Nat. Rev. Cancer 2002; 2: 957–964, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Grippo P. J., Sandgren E. P. Highly invasive transitional cell carcinoma of the bladder in a simian virus 40 T-antigen transgenic mouse model. Am. J. Pathol. 2000; 157: 805–813, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Holland E. C. Mouse models of human cancer as tools in drug development. Cancer Cell 2004; 6: 197–198, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• IARC. IARC Monogr. Eval. Carcinogen. Risks Hum. Chromium, Nickel and Welding. IARC, Lyon 1990; 49
   Google Scholar
• Kane A. B. Animal models of malignant mesothelioma. Environmental and occupational medicine, 3rd ed., W. N. Rom. Lippincott-Raven, Philadelphia 1998; 377–386
   Google Scholar
• Kane A. B. Mesothelial and mesothelioma cell lines. Malignant mesothelioma: Advances in pathogenesis, diagnosis, and translational therapies, H. I. Pass, N. J. Vogelzang, M. Carbone. Springer Science & Business Media, New York 2005; 87–98
   Google Scholar
• Lozano G., Zambetti G. P. What have animal models taught us about the p53 pathway?. J. Pathol. 2005; 2005: 206–220, [CROSSREF], [CSA]
   Google Scholar
• Lubet R., Wang Y., Zhang Z., You M. Mouse models incorporating alterations in the major tumor suppressor genes p53 and p16: Their use in screening for potential carcinogens, developing further relevant mouse models, and chemotherapeutic agents. Exp. Lung Res. 2005; 31: 117–133, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• MacDonald J., French J. E., Gerson R. J., Goodman J., Inoue T., Jacobs A., Kasper P., Keller D., Lavin A., Long G., McCullough B., Sistare F. D., Storer R., van der Laan J. W. The utility of genetically modified mouse assays for identifying human carcinogens: A basic understanding and path forward. Toxicol. Sci. 2004; 77: 188–194, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Manning C. B., Vallyathan V., Mossman B. T. Disease caused by asbestos: Mechanisms of injury and disease development. Int. Immunopharmacol. 2002; 2: 191–200, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• McClatchey A. I. Neurofibromatosis type II: Mouse models reveal broad roles in tumorigenesis and metastasis. Mol. Med. Today 2000; 6: 252–253, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• McClatchey A. I., Saotome I., Mercer K., Crowley D., Gusella J. F., Bronson R. T., Jacks T. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev. 1998; 12: 1121–1133, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Osaki M., Oshimura M., Ito H. PI3K-Akt pathway: Its function and alterations in human cancer. Apoptosis 2004; 9: 667–676, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Pershouse M. Inhal. Toxicol. 2006, In Press[CSA]
   Google Scholar
• Ramos-Niño M. E., Martinelli M., Scapoli L., Mossman B. T. Asbestos-induced mesothelioma. Malignant mesothelioma: Advances in pathogenesis, diagnosis, and translational therapies, H. I. Pass, N. J. Vogelzang, M. Carbone. Springer Science & Business Media, New York 2005; 21–33
   Google Scholar
• Rangarajan A., Weinberg R. A. Opinion: Comparative biology of mouse versus human cells: modeling human cancer in mice. Nat. Rev./Cancer 2003; 3: 952–959, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Robinson B. W. S., Musk A. W., Lake R. A. Malignant mesothelioma. Lancet 2005; 366: 397–408, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Saffiotti U. Mesothelioma carcinogenesis: In vivo models. Malignant mesothelioma: Advances in pathogenesis, diagnosis, and translational therapies, H. I. Pass, N. J. Vogelzang, M. Carbone. Springer Science & Business Media, New York 2005; 60–86
   Google Scholar
• Vaslet C. A., Messier N. J., Kane A. B. Accelerated progression of asbestos-induced mesotheliomas in heterozygous p53 +/− mice. Toxicol. Sci. 2002; 68: 331–338, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Zellos L., Christiani D. C. Epidemiology, biologic behavior, and natural history of mesothelioma. Thorac. Surg. Clin. 2004; 14: 469–477, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar